Martingale Asset Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Martingale Asset Management's RPRX Position: Q3 2026 in Review
Martingale Asset Management increased its Royalty Pharma (RPRX) stake by 0.17% in Q3 2026, buying an estimated $590 and bringing the position to 5,979 shares worth $349K. The position accounts for 0.01% of the portfolio, ranked #717.
Martingale Asset Management first reported a position in RPRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.25M in Q2 2025. 698 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.
- Martingale Asset Management held 5,979 shares of Royalty Pharma worth $349K as of Q3 2026.
- Martingale Asset Management bought 10 Royalty Pharma shares in Q3 2026, an estimated $590.
- Royalty Pharma made up 0.01% of Martingale Asset Management's portfolio in Q3 2026, its #717 holding.
- Martingale Asset Management first reported a position in Royalty Pharma in Q1 2024 and has held it in 8 quarters since.
- Martingale Asset Management's Royalty Pharma position peaked at $1.25M in Q2 2025.
- 698 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.
Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.